Among these, three drugs (APATORSEN, TRIAPINE, and MK-4721) currently in clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B, and PSCA, respectively. The gene discussed is RRM2B; the disease is posterior cortical atrophy.